Enabling personalized cancer medicine through analysis of gene-expression patterns

Nature

Volumn 452, Issue 7187, 2008, Pages 564-570

  Van 't Veer, Laura J ^a,b   Bernards, René ^a,b  

^a Agendia NV   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CANCER; DISEASE TREATMENT; DRUG; GENE EXPRESSION; MEDICINE; TUMOR;

CANCER GENETICS; DRUG RESPONSE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; PATIENT CARE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 41649114164     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06915     Document Type: Review

References (50)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352, 930-942 (1998).
2. Schena, M., Shalon, D., Davis, R. W. & Brown, P. O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
3. Fodor, S. P., Read, J. L., Pirrung, M. C., Lu, A. T. & Solas, D. Light-directed, spatially addressable parallel chemical synthesis. Science 251, 767-773 (1991).
4. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
5. Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005).
6. Bild, A. H., Potti, A. & Nevins, J. R. Linking oncogenic pathways with therapeutic opportunities. Nature Rev. Cancer 6, 735-741 (2006).
7. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006). This paper shows that the activation status of oncogenic pathways is associated with a characteristic gene-expression signature and that these signatures can be used both to determine a patient's prognosis and to predict his or her response to particular drugs.
8. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
9. Quackenbush, J. Computational analysis of microarray data. Nature Rev. Genet. 2, 418-427 (2001).
10. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
11. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
12. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
13. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000). This study shows that previously undetected and clinically significant subtypes of cancer can be identified by molecular classification of tumours on the basis of gene expression.
14. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
15. Ein-Dor, L., Zuk, O. & Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA 103, 5923-5928 (2006).
16. Desmedt, C. et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13, 3207-3214 (2007).
17. Buyse, M. et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192 (2006).
18. Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006).
19. Yu, J. X. et al. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer 7, 182, doi:10.1186/1471-2407-7-182 (2007).
20. Potti, A. et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355, 570-580 (2006).
21. Ma, X.-J. et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J. Clin. Oncol. 24, 4611-4619 (2006).
22. Harris, L. N. et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13, 1198-1207 (2007).
23. Dressman, H. K. et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12, 819-826 (2006).
24. Potti, A. et al. Genomic signatures to guide the use of chemotherapeutics. Nature Med. 12, 1294-1300 (2006).
25. Staunton, J. E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787-10792 (2001).
26. Lee, J. K. et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl Acad. Sci. USA 104, 13086-13091 (2007).
27. Coombes, K. R., Wang, J. & Baggerly, K. A. Microarrays: retracing steps. Nature Med. 13, 1276-1277 (2007).
28. Bonnefoi, H. et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 8, 1071-1078 (2007).
29. Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
30. Huang, E. et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nature Genet. 34, 226-230 (2003).
31. Saal, L. H. et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA 104, 7564-7569 (2007).
32. Hughes, T. R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
33. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006). In this study, a compendium of gene-expression profiles of cells subjected to known perturbations was used to find connections among small molecules that share a mechanism of action, between chemicals and physiological processes, and between drugs and diseases.
34. Hieronymus, H. et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10, 321-330 (2006).
35. Wei, G. et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10, 331-342 (2006).
36. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
37. Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007). This study used large-scale RNA-interference screens to identify oncogenic pathways that cause resistance to anticancer drugs in the clinic.
38. Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004).
39. Swanton, C. et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512 (2007).
40. Whitehurst, A. W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007).
41. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
42. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
43. Shi, L. et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nature Biotechnol. 24, 1151-1161 (2006).
44. Sparano, J. A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer 7, 347-350 (2006).
45. Mook, S. et al. Individualization of therapy using MammaPrint: from development to the MINDACT Trial. Cancer Genomics Proteomics 4, 147-155 (2007).
46. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
47. Harris, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007).
48. Rhodes, A. et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J. Clin. Pathol. 53, 125-130 (2000).
49. Ach, R. A. et al. Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics 8, 148, doi:10.1186/1471-2164-8- 148 (2007).
50. Hornberger, J., Cosler, L. E. & Lyman, G. H. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am. J. Manag. Care 11, 313-324 (2005).